Translational Development Acquisition Corp. (NASDAQ:TDACU – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 3 shares, an increase of 200.0% from the July 15th total of 1 shares. Based on an average daily trading volume, of 87 shares, the short-interest ratio is currently 0.0 days.
Translational Development Acquisition Stock Performance
Shares of TDACU remained flat at $12.57 on Friday. Translational Development Acquisition has a one year low of $10.71 and a one year high of $17.29. The firm has a 50 day moving average price of $12.04 and a 200-day moving average price of $11.20.
Translational Development Acquisition Company Profile
Translational Development Acquisition Corp. is a blank check acquisition company incorporated in Delaware. The company was formed to effect a merger, stock purchase, asset acquisition, stock exchange, reorganization or similar business combination with one or more businesses, though it has not yet identified a target for its initial transaction.
In early 2021, the company completed its initial public offering and listed its units on the Nasdaq under the ticker TDACU. Each unit comprises one Class A ordinary share and one-third of a warrant to purchase additional Class A shares, with its securities also trading separately as shares and warrants.
Following its IPO, the net proceeds from the offering are held in a trust account until the closing of an initial business combination.
Featured Stories
- Five stocks we like better than Translational Development Acquisition
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
